Outputs (10)

Cognitive Outcomes in Children Treated for Ependymoma Diagnosed Under 36 Months: A Systematic Review (2025)
Journal Article
Thomas, S., Morley, E., Ritzmann, T., Clayton, C., Powers, K., Airdrie, J., Robinson, L., Fifield, K., Packham, A., Oprandi, M. C., Lui, J., Whitfield, G., Thorp, N., Limond, J., & Grundy, R. (in press). Cognitive Outcomes in Children Treated for Ependymoma Diagnosed Under 36 Months: A Systematic Review. Pediatric Blood and Cancer, Article e31588. https://doi.org/10.1002/pbc.31588

It is crucial to understand the morbidity associated with treatments for young children with ependymoma given this is a high incidence age group also known to be at risk of poorer cognitive outcomes. This review aimed to identify the quality of exist... Read More about Cognitive Outcomes in Children Treated for Ependymoma Diagnosed Under 36 Months: A Systematic Review.

Metabolomic characterisation of the glioblastoma invasive margin reveals a region-specific signature (2024)
Journal Article
Wood, J., Smith, S. J., Castellanos-Uribe, M., Lourdusamy, A., May, S. T., Barrett, D. A., Grundy, R. G., Kim, D.-H., & Rahman, R. (2025). Metabolomic characterisation of the glioblastoma invasive margin reveals a region-specific signature. Heliyon, 11(1), Article e41309. https://doi.org/10.1016/j.heliyon.2024.e41309

Isocitrate dehydrogenase wild-type glioblastoma (GBM) is characterised by a heterogeneous genetic landscape resulting from dynamic competition between tumour subclones to survive selective pressures. Improvements in metabolite identification and meta... Read More about Metabolomic characterisation of the glioblastoma invasive margin reveals a region-specific signature.

Neurosurgical application of olaparib from a thermo-responsive paste potentiates DNA damage to prolong survival in malignant glioma (2024)
Journal Article
Serra, R., Smith, S. J., Rowlinson, J., Gorelick, N., Moloney, C., McCrorie, P., Veal, G. J., Berry, P., Chalmers, A. J., Suk, I., Shakesheff, K. M., Alexander, C., Grundy, R. G., Brem, H., Tyler, B. M., & Rahman, R. (2024). Neurosurgical application of olaparib from a thermo-responsive paste potentiates DNA damage to prolong survival in malignant glioma. British Journal of Cancer, 131, 1858-1868. https://doi.org/10.1038/s41416-024-02878-2

Background: There is increased pan-cancer specific interest in repurposing the poly adenosine diphosphate-ribose polymerase-1 (PARP-1) inhibitor, olaparib, for newly diagnosed or recurrent isocitrate dehydrogenase wild type glioblastoma. We explore w... Read More about Neurosurgical application of olaparib from a thermo-responsive paste potentiates DNA damage to prolong survival in malignant glioma.

Multi-omic approach identifies hypoxic tumor-associated myeloid cells that drive immunobiology of high-risk pediatric ependymoma. (2023)
Journal Article
Griesinger, A. M., Riemondy, K., Eswaran, N., Donson, A. M., Willard, N., Prince, E. W., Paine, S. M. L., Bowes, G., Rheaume, J., Chapman, R. J., Ramage, J., Jackson, A., Grundy, R. G., Foreman, N. K., & Ritzmann, T. A. (2023). Multi-omic approach identifies hypoxic tumor-associated myeloid cells that drive immunobiology of high-risk pediatric ependymoma. iScience, 26(9), Article 107585. https://doi.org/10.1016/j.isci.2023.107585

Ependymoma (EPN) is a devastating childhood brain tumor. Single-cell analyses have illustrated the cellular heterogeneity of EPN tumors, identifying multiple neoplastic cell states including a mesenchymal-differentiated subpopulation which characteri... Read More about Multi-omic approach identifies hypoxic tumor-associated myeloid cells that drive immunobiology of high-risk pediatric ependymoma..

Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: a multicenter study (2023)
Journal Article
Donson, A. M., Bertrand, K. C., Riemondy, K. A., Gao, D., Zhuang, Y., Sanford, B., Norris, G. A., Chapman, R. J., Fu, R., Willard, N., Griesinger, A. M., de Sousa, G. R., Amani, V., Grimaldo, E., Hankinson, T. C., Booker, F., Sill, M., Grundy, R. G., Pajtler, K. W., Ellison, D. W., …Ritzmann, T. A. (2023). Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: a multicenter study. Neuro-Oncology, 25(10), 1854-1867. https://doi.org/10.1093/neuonc/noad096

Background
Ependymoma (EPN) posterior fossa group A (PFA) has the highest rate of recurrence and the worst prognosis of all EPN molecular groups. At relapse, it is typically incurable even with re-resection and re-irradiation. The biology of recurre... Read More about Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: a multicenter study.

Pediatric-type high-grade neuroepithelial tumors with CIC gene fusion share a common DNA methylation signature (2023)
Journal Article
Sievers, P., Sill, M., Schrimpf, D., Abdullaev, Z., Donson, A. M., Lake, J. A., Friedel, D., Scheie, D., Tynninen, O., Rauramaa, T., Vepsäläinen, K. L., Samuel, D., Chapman, R., Grundy, R. G., Pajtler, K. W., Tauziède-Espariat, A., Métais, A., Varlet, P., Snuderl, M., Jacques, T. S., …Jones, D. T. W. (in press). Pediatric-type high-grade neuroepithelial tumors with CIC gene fusion share a common DNA methylation signature. npj Precision Oncology, 7, Article 30. https://doi.org/10.1038/s41698-023-00372-1

Pediatric neoplasms in the central nervous system (CNS) show extensive clinical and molecular heterogeneity and are fundamentally different from those occurring in adults. Molecular genetic testing contributes to accurate diagnosis and enables an opt... Read More about Pediatric-type high-grade neuroepithelial tumors with CIC gene fusion share a common DNA methylation signature.

Evaluating the efficacy and safety of single-agent etoposide intra-CSF chemotherapy in children and young people with relapsed/refractory central nervous system tumours (2023)
Journal Article
Butler, A., Meijer, L., Liu, J.-F., Chohan, M., Jalloh, I., Macarthur, D., Parr, M., Wilne, S., Wilson, S., Walker, D., Grundy, R., & Dandapani, M. (2023). Evaluating the efficacy and safety of single-agent etoposide intra-CSF chemotherapy in children and young people with relapsed/refractory central nervous system tumours. Child's Nervous System, 39, 1537-1544. https://doi.org/10.1007/s00381-023-05872-w

Purpose
The aim of the project was to evaluate intra-CSF etoposide administration in a palliative setting for children and young people with relapsed/refractory central nervous system (CNS) tumours, with the primary endpoints being overall survival... Read More about Evaluating the efficacy and safety of single-agent etoposide intra-CSF chemotherapy in children and young people with relapsed/refractory central nervous system tumours.

Optimising biomarkers for accurate ependymoma diagnosis, prognostication and stratification within International Clinical Trials: A BIOMECA study (2023)
Journal Article
Chapman, R. J., Ghasemi, D. R., Andreiuolo, F., Zschernack, V., Tauziede Espariat, A., Buttarelli, F. R., Giangaspero, F., Grill, J., Haberler, C., Paine, S. M., Scott, I., Jacques, T. S., Sill, M., Pfister, S., Kilday, J.-P., Leblond, P., Massimino, M., Witt, H., Modena, P., Varlet, P., …Biomarkers of Ependymoma in Childhood and Adolescence (BIOMECA) Consortium. (2023). Optimising biomarkers for accurate ependymoma diagnosis, prognostication and stratification within International Clinical Trials: A BIOMECA study. Neuro-Oncology, 25(10), 1871–1882. https://doi.org/10.1093/neuonc/noad055

Background Accurate identification of brain tumour molecular subgroups is increasingly important. We aimed to establish the most accurate and reproducible ependymoma subgroup biomarker detection techniques, across 147 cases from International Society... Read More about Optimising biomarkers for accurate ependymoma diagnosis, prognostication and stratification within International Clinical Trials: A BIOMECA study.

Dynamic susceptibility-contrast magnetic resonance imaging with contrast agent leakage correction aids in predicting grade in pediatric brain tumours: a multicenter study (2022)
Journal Article
Withey, S. B., MacPherson, L., Oates, A., Powell, S., Novak, J., Abernethy, L., Pizer, B., Grundy, R., Morgan, P. S., Bailey, S., Mitra, D., Arvanitis, T. N., Auer, D. P., Avula, S., & Peet, A. C. (2022). Dynamic susceptibility-contrast magnetic resonance imaging with contrast agent leakage correction aids in predicting grade in pediatric brain tumours: a multicenter study. Pediatric Radiology, 52(6), 1134-1149. https://doi.org/10.1007/s00247-021-05266-7

Background: Relative cerebral blood volume (rCBV) measured using dynamic susceptibility-contrast MRI can differentiate between low- and high-grade pediatric brain tumors. Multicenter studies are required for translation into clinical practice.

Ob... Read More about Dynamic susceptibility-contrast magnetic resonance imaging with contrast agent leakage correction aids in predicting grade in pediatric brain tumours: a multicenter study.

Assessing ‘second-look’ tumour resectability in childhood posterior fossa ependymoma—a centralised review panel and staging tool for future studies (2016)
Journal Article
Millward, C. P., Malluci, C., Jaspan, T., Macarthur, D., Heyward, R., Cox, T., Chong, K., & Grundy, R. G. (2016). Assessing ‘second-look’ tumour resectability in childhood posterior fossa ependymoma—a centralised review panel and staging tool for future studies. Child's Nervous System, 32, 2189–2196. https://doi.org/10.1007/s00381-016-3225-9